Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31371272 | 1.00 | KDM1A (0.45) | KDM1AHTR2AHTR2CHTR2BHSD11B1 | |
| SCHEMBL20859649 | 1.00 | KDM1A (0.45) | KDM1AHTR2AHTR2CHTR2BHSD11B1 | |
| SCHEMBL31351865 | 1.00 | KDM1A (0.45) | KDM1AHTR2AHTR2CHTR2BHSD11B1 | |
| SCHEMBL20859650 | 1.00 | KDM1A (0.45) | KDM1AHTR2AHTR2CHTR2BHSD11B1 | |
| SCHEMBL2610412 | 0.84 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL7708394 | 0.82 | CHRNA1 (0.35) | HSD11B1CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8244711 | 0.82 | CHRNA1 (0.35) | HSD11B1CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL15467278 | 0.82 | CHRNA1 (0.35) | HSD11B1CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2474866 | 0.82 | HTR2C (0.38) | HTR2AHTR2CHTR2BHSD11B1SLC6A4 | |
| SCHEMBL2482801 | 0.81 | MAOB (0.39) | HSD11B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049069-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MAN CO LTD (JP) | 2026-02-19 | — | — | US | disclosed |
| US-12479819-B2 | Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4506325-A2 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | Eisai R&D Management Co., Ltd. (JP) | 2025-02-12 | — | — | EP | disclosed |
| EP-3971164-B1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MAN CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| CN-119264110-A | Methods and compounds for preparing orexin-2 receptor antagonists, and reduced impurity lebol Lei Sheng | 卫材R&D管理有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118994106-A | Preparation method of diastereoisomer of lebol Lei Sheng | 福安药业集团重庆礼邦药物开发有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113727962-B | Methods and compounds for preparing orexin-2 receptor antagonists, and reduced impurity lebol Lei Sheng | 卫材R&D管理有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118047755-A | Synthesis method of lebol Lei Sheng | 四川奥邦古得药业有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-118047756-A | Preparation method of lebol Lei Sheng | 四川奥邦古得药业有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-1656349-B1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2011-10-12 | — | — | EP | disclosed |
| US-7834008-B2 | neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049069-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | HCRTR2, HCRTR1, NPY1R | KDM1A 1176/4885HTR2A 196/4885HTR2C 174/4885 |
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | HCRTR2, HCRTR1, MCHR2 | KDM1A 1071/4885HTR2A 154/4885HTR2C 142/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | KDM1A 1582/4885HTR2A 129/4885HTR2C 109/4885 |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | TACR2, SLC6A3, TACR1 | KDM1A 3544/4885HTR2A 1232/4885HTR2C 708/4885 |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | KDM1A 1249/4885HTR2A 133/4885HTR2C 152/4885 |
| US-12479819-B2 | Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities | HCRTR2, HCRTR1, MCHR2 | KDM1A 1071/4885HTR2A 154/4885HTR2C 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.